谭亚倩;卢浩扬;尚德为;王占璋;倪晓佳;张明;邓书华;朱秀清;胡晋卿;温预关;
TAN Yaqian;LU Haoyang;SHANG Dewei;WANG Zhanzhang;NI Xiaojia;ZHANG Ming;DENG Shuhua;ZHU Xiuqing;HU Jinqing;WEN Yuguan;The Affiliated Brain Hospital of Guangzhou Medical University;

• 1:广州医科大学附属脑科医院

摘要(Abstract)：

目的采用高效液相色谱串联质谱法(HPLC-MS/MS)建立测定人血清中奋乃静浓度的方法。方法色谱条件:色谱柱为Aglient XDB-C18(4.6 mm×50 mm,1.8μm);流动相为甲醇-水(90∶10,V/V,2 mmol·L-1甲酸铵);流速为0.7 m L·min-1;柱温35℃;进样量10μL。采用乙腈蛋白沉淀法前处理血清样本,定量离子对分别为m/z 404.15→m/z 171.15(奋乃静)和m/z 412.15→m/z 179.15(奋乃静-d8)。采用该方法对52例233份精神分裂症患者多次口服奋乃静后稳态药物浓度进行监测。结果奋乃静标准曲线方程为Y=2.014X-0.012 8(R2=0.998 6),线性范围为0.10～10.00 ng·m L-1。定量下限(0.10 ng·m L-1),低(0.30 ng·m L-1),中(3.00 ng·m L-1),高(7.50 ng·m L-1) 4个浓度的质控样品的批内和批间精密度RSD<15%,提取回收率分别为101.11%,95.37%,96.52%,101.32%。结论使用HPLC-MS/MS法检测奋乃静的血药浓度具有灵敏度高、可操作性强、结果准确度高等优点,可用于临床上奋乃静的血药浓度监测。
OBJECTIVE To develop a new method by HPLC-MS/MS for determination the concentration of perphenazine in human serum. CONCLUSION The concentration of perphenazine were measured by HPLC-MS/MS with a analytical column of Aglient XDB-C18( 4.6 mm× 50 mm,1.8 μm),The mobile phase were consisted of the methanol and water( 90 ∶ 10,V/V,plus 2 mmol·L-1 ammonium formate). The flow rate was 0.7 m L·min-1. The column temperature was set at 35 ℃ .And the injection volume was 10 μL.The serum specimens were treated by protein precipitation with acetonitrile. The ion transitions were m/z 404. 15 → m/z 171. 15( perphenazine) and m/z 412. 15 → m/z 179. 15( perphenazine-d8),respectively. Perphenazine concentrations of 233 human serum colleted from 52 schizophrenia patients were measured by this method. RESULTS The standard curve of perphenazine was Y = 2.014 X-0.012 8( R2= 0.998 6) within the linear ranges of 0.10-10.00 ng·m L-1. In the four concentrations of quality control sample of LLOQ( 0.10 ng·m L-1),LQC( 0.30 ng·m L-1),MQC( 3.00 ng·m L-1) and HQC( 7.50 ng·m L-1),the intra-and inter-assay precisions were lower than 15% and the recoveries were 101. 11%,95. 37%,96. 52% and 101. 32%,respectively. CONCLUSION The method ofdetermination perphenazine by HPLC-MS/MS is sensitive,applicable and precise,which is suitable for the therapeutic drug monitoring( TDM) for patients with perphenazine.

关键词(KeyWords)： 奋乃静;高效液相色谱串联质谱法;治疗药物监测
perphenazine;HPLC-MS/MS;therapeutic drug monitoring

Abstract:

Keywords:

基金项目(Foundation): 广东省自然科学基金资助项目(2018A0303130074);; 广州市卫生和计划生育科技项目(20191A011043);; 广州市荔湾区科技计划(201804017);; 广州市中医药和中西医结合科技项目(20202A011016);; 广州市卫生健康科技项目(20201A011047)

作者(Author): 谭亚倩;卢浩扬;尚德为;王占璋;倪晓佳;张明;邓书华;朱秀清;胡晋卿;温预关;
TAN Yaqian;LU Haoyang;SHANG Dewei;WANG Zhanzhang;NI Xiaojia;ZHANG Ming;DENG Shuhua;ZHU Xiuqing;HU Jinqing;WEN Yuguan;The Affiliated Brain Hospital of Guangzhou Medical University;

Email:

DOI:

参考文献(References)：

• [1]Hartung B,Sampson S,Leucht S.Perphenazine for schizophrenia[J].Cochrane Database of Systematic Reviews,2015,(3):CD003443．
• [2]曾承．奋乃静治疗酒精所致精神障碍疗效分析[J]．亚太传统医药，2011,7(2):82-84．
• [3]李敏雄，余庆华，蔡金亮等．奋乃静在重症监护病房患者镇静中的应用价值[J]．山西医药杂志，2016,45(23):2765-2766．
• [4]高剑峰．奋乃静血浓度与早期疗效及副反应的关系[J]．国外医学．精神病学分册，1991,1:64-65．
• [5]宋振铎，胡岱梅，原伟等．奋乃静治疗精神分裂症适宜血浓度研究[J]．中国现代医学杂志，2005,15(14):2176-2178．
• [6]Hiemke C,Bergemann N,Clement H W,et al.Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology:Update 2017[J].Pharmacopsychiatry,2018,51(1-2):9-62．
• [7]Noel C.A review of a recently published guidelines'"strong recommendation"for therapeutic drug monitoring of olanzapine,haloperidol,perphenazine,and fluphenazine[J].The Mental Health Clinician,2019,9(4):287-293．
• [8]朱军，黄伟侨，刘伟忠，等．反相高效液相色谱法测定人血浆奋乃静浓度[J]．医药导报，2007,26(7):733-734．
• [9]高建东，王涛，马广慈．流动注射分析法测定盐酸氟奋乃静血药浓度[J]．西北药学杂志，1996,11(1):27-28．
• [10]徐象珍，陈彬彬，吕海燕．同时检测人血浆中11种治疗精神病药物浓度的HPLC-MS/MS方法的建立[J]．中国药学杂志，2018,53(10):808-816．
• [11]阮灿军，果伟，周淼，等．HPLC-MS/MS偶联在线固相萃取技术同时定量测定人血清中6个精神科药物浓度[J]．药物分析杂志，2018,38(8):1393-1404．
• [12]国家药典委员会．中华人民共和国药典[M].4部．北京:化学工业出版社，2015:97．
• [13]张海苗，张博江，褚静，等．应用2015版Beers标准综合评价老年住院患者潜在不适当用药[J]．实用药物与临床，2018,21(4):448-451．
• [14]蹇在金．老年人临床用药特点[J]．岭南心血管病杂志，2011,17(3):183-187．
• [15]何欣．吸烟与精神分裂症患者药物疗效、副反应及血药浓度的关系[J]．世界最新医学信息文摘，2017,17(39):80．
• [16]邓伟良．饮酒能影响药效[J]．医学动物防制，2005,21(5):374．
• [17]马婉乐，孙雪，喻婉莹，等．慢性肾疾病和尿毒症毒素对非肾清除影响的研究进展[J]．中国临床药理学杂志，2016,32(9):861-864．
• [18]付国兰．心血管疾病患者精神科用药体会[J]．中国现代药物应用，2015,9(22):248-249.